COMMUNIQUÉS West-GlobeNewswire

RadNet, Inc. to Present at the Jefferies Healthcare Services Conference on September 29, 2025
26/09/2025
LOS ANGELES, Sept. 26, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated [...]
Dogecoin Cash, Inc. (OTCQB: DOGP) Subsidiary PrestoDoctor Expands Telehealth Cannabis Evaluations to Connecticut, Now Operating in 19 States Nationwide
26/09/2025
Now Operating in 19 States Nationwide Las Vegas, NV, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Cannabis Evaluations to Connecticut, Now Operating in 19 States Nationwide Mesquite, NV — September 26, 2025 — Dogecoin Cash, Inc [...]
BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented
26/09/2025
September 26, 2025 News Release BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented COPENHAGEN, DENMARK and BOSTON, MA, USA, September 26 – BioPorto A/S (“BioPorto” or the “ [...]
Concept Life Sciences Expands Integrated Drug Discovery Facilities
26/09/2025
Establishes one of the UK’s largest drug discovery research sites Site officially opened by local MP Jonathan Pearce CHAPEL-EN-LE-FRITH, United Kingdom, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Concept Life Sciences, a [...]
Fangzhou’s ‘XingShi’ LLM Featured by Nature News and Xinhua, Showcasing AI Innovation in Chronic Disease Care
26/09/2025
SHANGHAI, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, announced that its “XingShi” Large Language Model (“XS LLM”) was [...]
Ipsen et BioLabs Hôtel-Dieu décernent le Golden Ticket Ipsen 2025 à DETERA Therapeutics
26/09/2025
Paris, le 26 septembre 2025 – BioLabs Hôtel-Dieu, en partenariat avec Ipsen, annoncent aujourd'hui que DETERA Therapeutics s'est vu décerner le Golden Ticket Ipsen 2025 . Ce prix offre un an d'accès gratuit à un [...]
Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
26/09/2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy products [...]
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
26/09/2025
Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of Pluvicto TM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPC NATALEE five-year analysis of [...]
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025
26/09/2025
Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for [...]
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy
26/09/2025
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy NANTES, France – September 26, 2025, 7:00 a.m. – OSE Immunotherapeutics SA (ISIN: [...]
OSE Immunotherapeutics, Inserm Transfert et Nantes Université annoncent un partenariat stratégique pour accélérer l’innovation en immunothérapie
26/09/2025
OSE Immunotherapeutics, Inserm Transfert et Nantes Université annoncent un partenariat stratégique pour accélérer l’innovation en immunothérapie Nantes, le 26 septembre 2025, 7 heures – OSE Immunotherapeutics SA ( ISIN [...]
uniQure Announces Pricing of Upsized $300 Million Public Offering
26/09/2025
LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced [...]
Grant of Restricted Stock Units and Warrants to Employees in Genmab
26/09/2025
Company Announcement COPENHAGEN, Denmark; September 26, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 14,353 restricted stock units and 9,681 warrants to employees of the [...]
Lytus Technologies Holdings PTV. Ltd. Announces 1-for-2,500 Reverse Stock Split
26/09/2025
Dubai, United Arab Emirates, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Lytus Technologies Holdings PTV. Ltd. (OTCQB: LYTHF) (the “Company”), a leader in platform services and next-generation technology, today announced that it [...]
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
25/09/2025
Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 trials where [...]
EssilorLuxottica: Essilor Stellest is the first and only FDA market authorized spectacle lens in the United States
25/09/2025
Essilor Stellest is the first and only FDA market authorized spectacle lens in the United States EssilorLuxottica’s lens is clinically proven to slow myopia progression in children 1 ,2 Paris, France (25 September 2025 [...]
EssilorLuxottica: Essilor Stellest est le tout premier verre optique à recevoir de la FDA une autorisation de mise sur le marché aux États-Unis
25/09/2025
Essilor Stellest est le tout premier verre optique à recevoir de la FDA une autorisation de mise sur le marché aux États-Unis L’efficacité du verre d'EssilorLuxottica pour ralentir la progression de la myopie infantile [...]
Medirom Decides to Double Installation of Authentication Device “Orb” to 200 Stores, in Collaboration with “World” Co-founded by Sam Altman and Alex Blania
25/09/2025
TOKYO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; CEO: Kouji Eguchi; NASDAQ: MRM), a diversified healthcare company, has joined “World,” a “proof of human” [...]
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology
25/09/2025
– KOMET-001 in R/R NPM1 -m AML met its primary endpoint with ziftomenib monotherapy demonstrating significant clinical benefit and deep responses – – Consistent activity across pre-specified subgroups, regardless of [...]

Pages